

Press Release

SYNLAB International GmbH

Moosacher Straße 88
80809 Munich
Germany

Munich, 29 March 2022

SYNLAB partners with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany

- SYNLAB will provide high-quality, pan-cancer OncoDEEP® biomarker test to optimize prediction of patient responses to a wide range of approved and experimental therapies
- The comprehensive test will help oncologists decide on the most effective treatment for cancer patients
- With the partnership, SYNLAB further expands its substantive oncology services and continues its focus on personalised diagnostics and precision medicine

SYNLAB, Europe's leading medical diagnostics services provider, and OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, announce a partnership to provide oncologists with the high-quality, pan-cancer OncoDEEP® biomarker test in Germany. The comprehensive test helps to predict patient responses to a wide range of approved and experimental cancer therapies, further expanding SYNLAB's offering in personalised diagnostics and precision medicine in the field of oncology.

The test, which is covered by both private and public health insurance in Germany, is based on the analysis of over 600 genes and also includes the measurement of complex genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH). All with the aim of determining whether a patient may be eligible for targeted treatment or immunotherapy. In certain cancer types, such as HER2-positive breast cancer, immunohistochemistry (IHC) analyses will also be performed to measure protein expression and reveal patients eligibility to anti-cancer drugs.

Dr. Christian Mayer, head of human genetics, pathology and cytology at SYNLAB Germany, underlines the innovative aspect of the new test: "OncoDEEP is a real asset for oncology diagnostics offering in Germany. Particularly in comparison to a single biomarker test, the chance to comprehensively test and predict patient responses to a variety of treatments provides significant benefit to patients and doctors and ultimately delivers accurate decision support on the most effective treatment options."

Bernard Courtieu, CEO of OncoDNA, agrees and sees broad value in the new partnership: "We are delighted to transfer our OncoDEEP technology to further enhance SYNLAB in the field of molecular diagnostics for clinical oncology. Biomarker testing has the potential to improve patient outcomes and health quality. Improving access to these tests should be a priority worldwide. This collaboration will further support the uptake of precision medicine across Germany."



For more information:

Media contact: Diana Tabor, FTI Consulting	+49 (0) 151 46693856 media-contact@synlab.com
Investor contact: Mark Reinhard, SYNLAB	+49 (0) 170 118 3753 mark.reinhard@synlab.com

About SYNLAB

- SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates.
- Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
- SYNLAB operates in 36 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 30,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.
- SYNLAB performed around 600 million laboratory tests and achieved revenues of €3.76 billion in 2021.
- More information can be found on www.synlab.com